Prognosis of small cell lung cancer patients with diabetes treated with metformin

Clinical and Translational Oncology

Volumn 17, Issue 10, 2015, Pages 819-824

  Xu, T ^a   Liang, G ^b   Yang, L ^a   Zhang, F ^a  

^a Tianjin Hospital of ITCWM   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Diabetes; Metformin; Prognosis; Small cell lung cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ETOPOSIDE; INSULIN; IRINOTECAN; LACTATE DEHYDROGENASE; MEGLITINIDE; METFORMIN; NEURON SPECIFIC ENOLASE; PLATINUM; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; FEMALE; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SMALL CELL LUNG CANCER; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ETOPOSIDE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; MALE; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATINUM COMPOUNDS; PNEUMONECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA;

EID: 84941876591     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1311-1     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.
3. Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2006;24:4840–7.
4. Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45:105–17.
5. Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw. 2008;6:323–31.
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
7. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2:48–53.
8. Wu L, Rabe KG, Petersen GM. Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk? PLoS One. 2015;10:e0117230.
9. Gong Y, Wei B, Yu L, Pan W. Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies. Oral Oncol. 2015;51:332–40.
10. Yeo Y, Ma SH, Hwang Y, Horn-Ross PL, Hsing A, Lee KE, et al. Diabetes mellitus and risk of thyroid cancer: a meta-analysis. PLoS ONE. 2014;9:e98135.
11. Ma FJ, Liu ZB, Qu L, Hao S, Liu GY, Wu J, et al. Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People’s Republic of China. Onco Targets Ther. 2014;7:2147–54.
12. Wolf I, Sadetzki S, Gluck I, Oberman B, Ben-David M, Papa MZ, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006;42:1077–82.
13. Hjartaker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008;630:72–93.
14. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118:1202–11.
15. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19:5372–80.
16. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer. 2011;117:5103–11.
17. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, et al. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015;191:448–54.
18. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23:1771–80.
19. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22:2640–5.
20. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.
21. Adelstein DJ, Tomashefski JF Jr, Snow NJ, Horrigan TP, Hines JD. Mixed small cell and non-small cell lung cancer. Chest. 1986;89:699–704.
22. Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–9.
23. Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12.
24. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–97.
25. Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W, et al. Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer. Am J Cancer Res. 2014;4:874–85.
26. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299–304.
27. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012;12:410.
28. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013;108:2021–32.
29. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112:1809–14.
30. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898–906.
31. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen–induced lung tumorigenesis. Cancer Prev Res (Phila). 2010;3:1066–76.